Baimai Bio completed the Series A financing of over 50 million yuan
Biomai is a tumor immunotherapy drug developer. Its core direction is to develop innovative drug preparations for tumor immunotherapy. It is expected to synergize with existing clinical tumor treatment technologies and significantly enhance its efficacy. At the same time, the company is still Research and development of new interventional therapy technology for tumors and new […]
Baimai Bio completed the Series A financing of over 50 million yuan Read More »